ANNOVIS BIO (ANVS) Stock Price & Overview
NYSE:ANVS • US03615A1088
Current stock price
The current stock price of ANVS is 2.37 USD. Today ANVS is down by -5.2%. In the past month the price increased by 4.6%. In the past year, price increased by 51.52%.
ANVS Key Statistics
- Market Cap
- 67.213M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.40
- Dividend Yield
- N/A
ANVS Stock Performance
ANVS Stock Chart
ANVS Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ANVS. When comparing the yearly performance of all stocks, ANVS is one of the better performing stocks in the market, outperforming 72.51% of all stocks.
ANVS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ANVS. While ANVS has a great health rating, there are worries on its profitability.
ANVS Earnings
ANVS Forecast & Estimates
10 analysts have analysed ANVS and the average price target is 14.03 USD. This implies a price increase of 491.77% is expected in the next year compared to the current price of 2.37.
ANVS Groups
Sector & Classification
ANVS Financial Highlights
Over the last trailing twelve months ANVS reported a non-GAAP Earnings per Share(EPS) of -1.4. The EPS increased by 23.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -136.87% | ||
| ROE | -171.23% | ||
| Debt/Equity | 0 |
ANVS Ownership
ANVS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.83 | 362.351B | ||
| AMGN | AMGEN INC | 15.27 | 188.551B | ||
| GILD | GILEAD SCIENCES INC | 15.62 | 170.497B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.14 | 114.627B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.86 | 77.866B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.29 | 40.669B | ||
| INSM | INSMED INC | N/A | 31.035B | ||
| NTRA | NATERA INC | N/A | 28.359B | ||
| BIIB | BIOGEN INC | 11.44 | 26.951B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.81 | 22.845B | ||
| MRNA | MODERNA INC | N/A | 20.253B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.149B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ANVS
Company Profile
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). The company is headquartered in Malvern, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2020-01-29. The firm is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.
Company Info
IPO: 2020-01-29
ANNOVIS BIO
101 Lindenwood Drive, Suite 225
Malvern PENNSYLVANIA 19312 US
CEO: Maria Maccecchini
Employees: 8
Phone: 14848753192
ANNOVIS BIO / ANVS FAQ
Can you describe the business of ANNOVIS BIO?
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). The company is headquartered in Malvern, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2020-01-29. The firm is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.
What is the stock price of ANNOVIS BIO today?
The current stock price of ANVS is 2.37 USD. The price decreased by -5.2% in the last trading session.
Does ANVS stock pay dividends?
ANVS does not pay a dividend.
What is the ChartMill technical and fundamental rating of ANVS stock?
ANVS has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the ownership details for ANVS stock?
You can find the ownership structure of ANNOVIS BIO (ANVS) on the Ownership tab.
Can you provide the short interest for ANVS stock?
The outstanding short interest for ANNOVIS BIO (ANVS) is 12.25% of its float.